focus -WSS

focus

author：knowledge 2025-10-02 13:40:56 - browse：89918

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Boeing's 1st astronaut flight bumped into next year, more repairs needed

knowledge

WSS

NYC plans to house migrants on an island in the East River

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Biden declares emergency in flood

'The Exorcist' director William Friedkin dead at 87

Biden’s NIH nominee is languishing in Congress

NYC plans to house migrants on an island in the East River

focus

focus

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Pandemic and All Hazards Preparedness Act needs lean update

Affirmative action in medical school literally saved lives

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Continuity nursing helped my family in our darkest PICU moments

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

What does generative AI mean for health care? We asked experts

Eisai exec who led development of Alzheimer’s drug to retire

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Democratic lawmaker calls for 'well

focus

Illinois to ban advertising for guns allegedly marketed to kids and militants

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

ACA's risk program benefits Blue Cross Blue Shield insurers

Create a giant ice tray with this foil pan hack to keep food cold this summer

Wikipedia

knowledge

explore

focus